SAN FRANCISCO — Upon FDA approval of the fixed-dose glaucoma treatment Rocklatan, Aerie Pharmaceuticals’ next step is launching the product.
U.S. physicians are “excited about using it in their practices,” Aerie president and chief operating officer Tom Mitro told Healio.com/OSN during the American Glaucoma Society meeting.
Rocklatan (netarsudil 0.02%/latanoprost 0.005% ophthalmic solution) is indicated for reduction of IOP in patients with open-angle glaucoma or ocular hypertension. The approval, which Aerie announced on March 12, is based on data from two phase 3
Uncategorized